Sea snake homing instinct could nix translocation
Philippine researchers want to restore a sea snake that has been wiped out on Gato Island by translocating the species from other islands. But new research suggests that this may not work because these snakes have such a strong drive to return to their own islands. ...... "The fidelity of snakes to their home island was absolute," say Sohan Shetty, then at the University of Sydney, Australia, and...Abgenix to become sole owner of Xenomouse fully human antibody technology
. Contact: . Kurt Leutzinger. Vice President and Chief Financial Officer . Abgenix Inc.. (510) 608-6575. or. Marion E. Glick. Porter Novelli. 212/601-8273 . . ABGENIX TO BECOME SOLE OWNER OF XENOMOUSE FULLY HUMAN ANTIBODY TECHNOLOGY. -Abgenix to Acquire Japan Tobacco's Interests in Xenotech Joint Venture -. . FREMONT, CALIFORNIA - December 20, 1999 - Abgenix, Inc. (Nasdaq: ABGX) will become t.... Contact: . Kurt Leutzinger . Abgenix, Inc.. Vice President and . Chief Financial Officer. (510) 608-6575. . Marion E. Glick. Porter Novelli. (212) 601-8273 . . Mark R. Vincent. CuraGen Corporation. Director, Corporate Communications. 1-888-GENOMICS. www.curagen.com. . . ABGENIX AND CURAGEN ESTABLISH LARGE-SCALE DRUG DEVELOPMENT ALLIANCE. Companies to Develop Genomics-based Human Antibody Drug...Abgenix initiates phase III clinical trial of graft versus host disease therapy
. . . . . Abgenix to Seek a Corporate Partner to Commercialize ABX-CBL . . FREMONT, Calif., December 7, 1999 - Abgenix, Inc. (Nasdaq: ABGX) is initiating a Phase III. clinical trial comparing its antibody, ABX-CBL, with standard therapy for patients with. steroid-resistant graft-versus-host disease (srGVHD), a serious, life-threatening disorder. Abgenix. also indicated that it would seek a...Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
. . . FREMONT, Calif., November 30, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today reported top level results. of its Phase I/II clinical trial with ABX-IL8, a fully human antibody developed with the company's. XenoMouse™ technology. Additional details will be presented at the Psoriasis: from Gene to Clinic. meeting in London on December 2,1999. The multi-center, placebo controlled trial inv.... Contact: . Kurt Leutzinger. Vice President and. Chief Financial Officer . Abgenix Inc.. (510) 608-6575. and. Marion E. Glick. Porter Novelli. 212/601-8273 . . Arthur Mandell. Senior Vice President, Corporate and Business Development. Human Genome Sciences. 301/309-8504. and . Kate de Santis. Director, Corporate Communications and Investor Relations. Human Genome Sciences . 301/251-6003 . . H.... FREMONT, CALIF., December 1, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has.signed a research license and option agreement with Chiron, Inc. ("Chiron") (Nasdaq: CHIR) under which.Chiron will use Abgenix's XenoMouse™ technology to generate fully human monoclonal antibodies to.an undisclosed antigen in the field of autoimmune diseases. In return, Abgenix will receive a.tech...Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
. . .FREMONT, Calif., March 15, 1999 -- Abgenix, Inc. (Nasdaq: ABGX) reported today.in Cancer Research (Volume 59, Issue no. 6), encouraging results of preclinical.studies with its proprietary fully human monoclonal antibody, ABX-EGF. Developed.using the company's XenoMouseTM technology, ABX-EGF targets the receptor for.human epidermal growth factor (EGFr) which is overexpressed on many major h...A Phoenix From A Ring Of Fire Is A Pattern For The Recovery Of Mount St. Helens
. .A lush volcanic island in Indonesia provides clues about Mount St. .Helens' recovery from its moon-like state . .On August 27, 1883, the volcano Krakatau in the Dutch East Indies erupted with the .force of more than 10,000 Hiroshima-type hydrogen bombs, killing an estimated 30,000 .people and leaving a wide swath of devastation. The recovery from that volcanic upheaval .is providi...